SCHEMBL5293398

SCHEMBL5293398

O=S(=O)(Nc1cccc2nsnc12)c1ccc(Oc2ccc(C(F)(F)F)cc2Cl)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.47
MEN1 O00255 5/20 0.47
MAPT P10636 4/20 0.47
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
POLB P06746 2/20 0.42
CASP6 P55212 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SLC40A1 Q9NP59 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 2/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
PTGES2 Q9H7Z7 1/20 0.41
CCKBR P32239 1/20 0.41
SCN9A Q15858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6391201 0.75 MEN1 (0.45) KMT2AMEN1MAPTKDM4EPKM
SCHEMBL8159388 0.74 KMT2A (0.52) KMT2AMEN1KDM4EPOLBSMN1; SMN2
SCHEMBL5282153 0.71 MEN1 (0.63) KMT2AMEN1MAPTKDM4EPKM
SCHEMBL5246316 0.71 MEN1 (0.49) KMT2AMEN1MAPTKDM4EPKM
SCHEMBL5285892 0.69 MEN1 (0.66) KMT2AMEN1MAPTKDM4EPKM
SCHEMBL1153731 0.69 KMT2A (0.60) KMT2AMEN1MAPTPOLBSMN1; SMN2
SCHEMBL5245777 0.68 MEN1 (0.77) KMT2AMEN1MAPTKDM4EPKM
SCHEMBL10984838 0.68 MAPT (0.64) KMT2AMEN1MAPTKDM4EPOLB
SCHEMBL11015697 0.67 MEN1 (0.47) KMT2AMEN1MAPTPOLBTDP1
SCHEMBL5246622 0.67 MEN1 (0.67) KMT2AMEN1MAPTKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP KMT2A 1303/4885MEN1 3562/4885MAPT 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.